Search company, investor...

Nutrinia

nutrinia.com

Stage

Series D | Alive

Total Raised

$42M

Last Raised

$30M | 6 yrs ago

About Nutrinia

Nutrinia is a neonatology company focused on developing a proprietary oral formulation of insulin for gastrointestinal indications in infants.

Headquarters Location

6 Ha’khilazon Street 6th Floor

Ramat Gan, 5252270,

Israel

+972 3 7262262

Missing: Nutrinia's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Nutrinia's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Nutrinia

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nutrinia is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Diabetes

1,903 items

Nutrinia Patents

Nutrinia has filed 14 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Food ingredients
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/24/2017

8/14/2018

Diabetes, Digestive system, Gastrointestinal tract disorders, Syndromes, Stomach disorders

Grant

Application Date

3/24/2017

Grant Date

8/14/2018

Title

Related Topics

Diabetes, Digestive system, Gastrointestinal tract disorders, Syndromes, Stomach disorders

Status

Grant

Latest Nutrinia News

Nutrinia Raises $30M to Continue Development of Specialized Oral Insulin

Aug 22, 2016

Verify here. The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com. All rights reserved. All other trademarks recognized. Copyright © 1997-2016 BioPortfolio Limited. Site developed by Alacrify Ltd .

Nutrinia Frequently Asked Questions (FAQ)

  • Where is Nutrinia's headquarters?

    Nutrinia's headquarters is located at 6 Ha’khilazon Street, Ramat Gan.

  • What is Nutrinia's latest funding round?

    Nutrinia's latest funding round is Series D.

  • How much did Nutrinia raise?

    Nutrinia raised a total of $42M.

  • Who are the investors of Nutrinia?

    Investors of Nutrinia include OrbiMed Advisors, Pontifax, WuXi Healthcare Ventures, TPG Biotech, H.I.G. BioHealth Partners and 3 more.

  • Who are Nutrinia's competitors?

    Competitors of Nutrinia include Humanetics, Deciphera Pharmaceuticals, InClinica, Tolera Therapeutics, GC-Rise Pharmaceutical and 11 more.

Compare Nutrinia to Competitors

M
Morria Biopharmaceuticals

Morria's lead products are first-in-class synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAID). These drugs target a known but previously elusive key event in the inflammation process upstream of current competitors while simultaneously protecting cells and tissues against inflammatory damage and stimuli. Morria has two lead products (MRX4 for allergic rhinitis and MRX6 for contact dermatitis) scheduled for clinical trials in late 2007 and a growing library of additional compounds. Double blind placebo controlled human pilot-studies for contact dermatitis have been successfully completed in Israel .nMorria is also currently engaged in research agreements with three global pharmaceutical leaders in the fields of ophthalmology, eye-care and cardiovascular medicine.

G
GC-Rise Pharmaceutical

GC-Rise Pharmaceutical is a pharmaceutical company that aims to bring Western natural medicine with proven clinical benefits to China. The company received approval for Remifemin for natural treatment for post-menoposal symptoms from the Chinese regulatory authorities (SFDA) after successfully conducting clinical trials in China. The company has launched other products and is currently developing additional natural derived medicine in China.

I
Inflabloc Pharmaceuticals

Inflabloc Pharmaceuticals, Inc. is engaged in the research and development of pharmaceutical treatments for inflammatory disorders. Inflabloc's current product development is based on its discoveries of strong anti-inflammatory properties of dehydroepiandrosterone (DHEA), a steroid that is produced in the adrenal gland. The company's lead product line is a DHEA combination treatment. The company has 4 products in development. IP-1001 is slated to enter Phase 2 clinical trials in Crohn's disease later this year. IP-1002 has completed Phase 1. IP-1003 recently established proof-of-concept in an inflammatory bowel disease (IBD) animal model, while IP-1005 has just entered proof-of-concept testing in a C-reactive protein (CRP) mouse model.

I
INDENA SPA

Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

InClinica Logo
InClinica

InClinica, formerly IndiPharm, is a global clinical CRO that specializes in leading companies through clinical trials, and works across all phases of clinical development, with a particular strength in assisting small to mid-sized companies.

C
Calyx Therapeutics

Calyx Therapeutics is a pharmaceutical company focusing on oral therapies for diabetes and inflammatory diseases. Calyx utilizes natural plant extracts with demonstrated clinical activity in humans as the source of its discovery efforts. The company isolates the biologically active molecule, determines its chemical structure, and aims to develop small molecule analogs. This process aims to reduce the time and investment required to take lead molecules into preclinical and clinical testing.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.